Paroxysmal Nocturnal Hemoglobinuria (PNH)

Dr. Meyers was born and raised in rural Northern California and traveled around the country during her medical training. She developed an interest in hematology and oncology during medical school, and pursued a fellowship in that field after her internal medicine residency. While at the University of Utah, she performed laboratory research on bone marrow failure syndromes, with a focus on paroxysmal nocturnal hemoglobinuria. Her research continues at OHSU, and she currently has government and private foundation support to study the genetic changes that lead to bone marrow dysfunction and

After obtaining a BA/MS as a Vagelos Scholar in Molecular Life Sciences at the University of Pennsylvania in 2003, Dr. Lee received his MD from the University of Miami in 2007. Following his internal medicine residency at the University of Alabama at Birmingham, he completed his fellowship in hematology and oncology at the New York Presbyterian Hospital/Columbia University Medical Center from 2010-2013 where he focused on epigenetics of myelodysplastic syndromes (MDS) under Drs. Azra Raza and Benjamin Tycko. In July 2013, Dr. Lee was recruited to serve in the Leukemia Program in the Division

Dr. Hofmann Zhang, a UW Health pediatrician, who specializes in pediatric bone marrow transplant and hematology, first established her research and clinical career in the Northeast. Following her medical school experience – MD from Albert Ludwigs University of Freiburg, Germany, in 2000 – Hofmann completed her pediatric residency at the University of California in San Francisco. Upon completion of her residency, Hofmann began a prolific stint in pediatric hematology and oncology at the Dana-Farber/Boston Children’s Cancer and Blood Disorder Center at Harvard Medical School, and in

Dr. Griffiths am board certified in hematology, oncology and internal medicine and hold medical licenses in New York and Maryland. She is a member of multiple professional organizations, including the American Society of Hematology, the American Association for Cancer Research, the Society for Immunotherapy of Cancer and the American Society of Oncology. Her research is focused on the mechanism of hypomethylating drugs (HMAs) in patients with myeloid cancer, specifically the contribution of the immune system to these responses. They have examined how HMAs can cause re-expression of proteins in

Lucy A. Godley, MD, PhD, is an expert in the care and treatment of patients with diseases of the bone marrow, including leukemias, lymphomas and multiple myeloma. She also cares for patients undergoing stem cell transplantation and patients with benign hematologic conditions.